Company Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 254 |
| CEO | Grant E. Pickering M.B.A. |
Contact Details
Address: 825 Industrial Road San Carlos, California United States | |
| Website | https://vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer & Director |
| Andrew L. Guggenhime M.B.A. | President & Chief Financial Officer |
| James Wassil M.B.A., M.S. | Executive Vice President & Chief Operating Officer |
| Whitney Jones | Chief People Officer |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder |
| Dr. Jeff Fairman Ph.D. | Co-Founder & Vice President of Research |
| Elvia Cowan | Senior Vice President of Finance & Principal Accounting Officer |
| Janet Graesser | Senior Vice President of Corporate Communications & Investor Relations |
| Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary |
| Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Dec 19, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 21, 2024 | 8-K | Current Report |